Abstract:Background Resveratrol (RSVL) is a plant-derived polyhydroxyphenolic compound with excellent anticancer properties, alone or in combination with other chemotherapeutic drugs. However, the anticancer mechanism of RSVL is diverse and high concentrations are often required for RSVL to exert its anticancer effect, which would also adversely affect normal cells. Purpose The main objective of this study is to investigate the molecular mechanism of how non-cytotoxic concentrations of RSVL enhance the anticancer effect of cisplatin involving a newly identified RSVL-binding protein. Methods Cell viability of cell lines from three cancer types exposed to RSVL and/or cisplatin was measured by NBB staining assay. RSVL-binding proteins were identified using RSVL-bound CNBr-activated Sepharose 4B beads coupled with LC-MS/MS, and the binding between RSVL and novel RSVL-binding protein was further confirmed with an in vitro pull-down assay. The expression of proteins was examined by immunoblot analysis, and the activity of methyltransferase was evaluated by in vitro methylation assay. The methylation level of H3R17 in the gene promoter was investigated using ChIP-qPCR. Bioinformatics analysis was conducted to identify pathway enrichment of genes, predict drug sensitivity, and analyze the survival of cancer patients. Results Low doses of RSVL might promote cancer cell growth whereas high doses of RSVL showed cytotoxic effects on normal cells. When co-treated with a lower cisplatin dose, non-cytotoxic RSVL levels showed synergistic anticancer effects. Here, coactivator-associated arginine methyltransferase 1 (CARM1) was identified as a novel RSVL-binding protein, and we showed that the upregulation of CARM1 increased the sensitivity of cancer cells to RSVL. Interestingly, we found that CARM1 was essential in the RSVL-induced sensitivity of cisplatin. Further molecular mechanistic studies revealed that RSVL could stabilize CARM1 protein, resulting in the upregulation and increased methyltransferase activity of CARM1. Additionally, we showed that the methylation levels of H3R17 in the promoter of p21 , a downstream gene of CARM1 involving cell cycle arrest, were significantly increased after RSVL treatment. Finally, data from our bioinformatics analysis suggested that CARM1 could be utilized as a potential biomarker for chemotherapeutic drug sensitivity and prognosis in cancers. Conclusions This study identified CARM1 as a RSVL-binding protein for the first time and elucidated the potential roles of CARM1 in enhancing the efficacy of cisplatin by low doses of RSVL, which could have important clinical implications.

Ribosome Biogenesis Regulator 1 Homolog (RRS1) Promotes Cisplatin Resistance by Regulating AEG-1 Abundance in Breast Cancer Cells

Effect of Lung Resistance-Related Protein on the Resistance to Cisplatin in Human Ovarian Cancer Cell Lines.

The role of RRS1 in breast cancer cells metastasis and AEG-1/AKT/c-Myc signaling pathway

RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced NSCLC Patients Treated with Cisplatin-Based Chemotherapy

Nuclear Orphan Receptor ERRα Promotes Cisplatin Resistance in Breast Cancer Cells by Targeting CCNE2

Rps15a Imparts Chemoresistance by Regulating Cd44 Expression and Cell Stemness in Esophageal Squamous Cell Carcinoma

Upregulation of ZNRD1 Enhances Cisplatin Resistance in Human Esophageal Cancer Cells by Regulation of ERCC1 and Bcl-2

LRPPRC Contributes to the Cisplatin Resistance of Lung Cancer Cells by Regulating MDR1 Expression

RRS1 Silencing Suppresses Colorectal Cancer Cell Proliferation and Tumorigenesis by Inhibiting G2/M Progression and Angiogenesis

ERRα confers oncogenesis and cisplatin resistance via transcriptionally activating CCNE2 in breast cancer

SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells

Effect of the BRCA1-SIRT1-EGFR Axis on Cisplatin Sensitivity in Ovarian Cancer.

Downregulated RRS1 inhibits invasion and metastasis of BT549 through RPL11-c-Myc-SNAIL axis

Non-cytotoxic levels of resveratrol enhance the anticancer effects of cisplatin by increasing the methyltransferase activity of CARM1 in human cancer cells

SH3RF2 Contributes to Cisplatin Resistance in Ovarian Cancer Cells by Promoting RBPMS Degradation

BRSK1 confers cisplatin resistance in cervical cancer cells via regulation of mitochondrial respiration

m6A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma

Down-regulation of Ras-related Protein Rab 5C-Dependent Endocytosis and Glycolysis in Cisplatin-resistant Ovarian Cancer Cell Lines

Silencing CDR1as Enhances the Sensitivity of Breast Cancer Cells to Drug Resistance by Acting As a Mir‐7 Sponge to Down‐regulate REGγ

CXCR4 Promotes Cisplatin-Resistance of Non-Small Cell Lung Cancer in a CYP1B1-dependent Manner.

RMP/URI Inhibits Both Intrinsic and Extrinsic Apoptosis Through Different Signaling Pathways